|
| |
 |
| |
|
| |
| Latest News |
ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous
Cell Carcinoma of the Head and Neck Supplemental Biologics Application for
ERBITUX® in U.S.
>>more
|
|
|
|
 |
| |
ImClone Systems is a fully integrated global biopharmaceutical company committed to advancing oncology care
by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients
with a variety of cancers.
On November 24, 2008, ImClone Systems became a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY).
View the November 24, 2008 press release
Additional information about Lilly is available at www.lilly.com
|
|
